Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research

Emerging degrader technologies engaging lysosomal pathways

Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions

Autophagy mediated targeting degradation, a promising strategy in drug development

Recent advances in targeted protein degraders as potential therapeutic agents

Advancing targeted protein degradation for metabolic diseases therapy

Perspectives of Autophagy-Tethering Compounds (attecs) in Drug Discovery

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy

Targeted protein degradation in drug development: Recent advances and future challenges

Autophagy‐mediated targeted protein degradation

Targeting the Undruggables ---- the Power of Protein Degraders

Novel approaches to targeted protein degradation technologies in drug discovery

Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives

[Advances of targeted protein degradation technology and its applications in diseases therapy].

Emerging Targeted Protein Degradation Tools for Innovative Drug Discovery: from Classical PROTACs to the Novel and Beyond.

Major Advances in Emerging Degrader Technologies.

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]

Targeted protein degradation in mammalian cells: A promising avenue toward future

Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy

Development of natural product-based targeted protein degraders as anticancer agents